Metraipolis › archive › dc_dd57adfa617a

Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for… — Europe PMC PMID:41964212

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41964212
DOI
10.1002/cam4.71745
License (as archived)
solo-consultazione
Archived
2026-10-08T06:02:52.038Z
SHA-256 of the archived text
b28bf8ececdb30b65b78b46a1b4ebbd242e3fb2f30520f9b287633309cff086c
Stable URL of this page
https://metraipolis.com/documento/dc_dd57adfa617a

How to cite

Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for… — Europe PMC PMID:41964212 — Europe PMC (en), https://europepmc.org/article/MED/41964212 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dd57adfa617a (Metraipolis archive dc_dd57adfa617a, sha256 b28bf8ececdb30b65b78b46a1b4ebbd242e3fb2f30520f9b287633309cff086c)
BibTeX
@misc{dcdd57adfa617a,
  title = {Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for… — Europe PMC PMID:41964212},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41964212},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dd57adfa617a; sha256 b28bf8ececdb30b65b78b46a1b4ebbd242e3fb2f30520f9b287633309cff086c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41964212. Agents can read the archived copy with the MCP tool read_document.